

Supplementary material

Articles used for case reports

- 1 **Abu-Amer N**, Dinour D, Mini S, Beckerman P. An Unusual Case of Metabolic Acidosis: Clinical Case Education. *Isr Med Assoc J* 2019; **21**: 766-768 [PMID: 31713370]
- 2 **Adachi J**, Inaba Y, Maki C. Euglycemic Diabetic Ketoacidosis with Persistent Diuresis Treated with Canagliflozin. *Intern Med* 2017; **56**: 187-190 [PMID: 28090050 DOI: 10.2169/internalmedicine.56.7501]
- 3 **Ahmed T**, Karimi H, Hegde V, Lodhi SH. Euglycemic Diabetic Ketoacidosis Due to SGLT2 Inhibitor in a Patient With Gitelman Syndrome: A Therapeutic Dilemma. *Cureus* 2021; **13**: e19169 [PMID: 34873512 DOI: 10.7759/cureus.19169]
- 4 **Ahn T**, Teloken P, Burke P. Sodium-glucose linked transporter 2 inhibitor associated post-operative euglycaemic diabetic ketoacidosis: an important consideration for all surgeons. *ANZ J Surg* 2019; **89**: 982 [PMID: 31379074 DOI: 10.1111/ans.15307]
- 5 **Alhassan S**, Rudoni M, Alfonso-Jaume MA, Jaume JC. Protracted glycosuria after discontinuation of sodium-glucose cotransporter 2 inhibitors: Implications for weekly dosing and extended risk of euglycemic diabetes ketoacidosis. *J Diabetes* 2019; **11**: 410-411 [PMID: 30552748 DOI: 10.1111/1753-0407.12885]
- 6 **Alhemeiri M**, Alseddeeqi E. Euglycemic Diabetic Ketoacidosis after Discontinuing SGLT2 Inhibitor. *Case Rep Endocrinol* 2022; **2022**: 4101975 [PMID: 35282610 DOI: 10.1155/2022/4101975]
- 7 **Alkatheeri A**, Alseddeeqi E. Euglycemic diabetic ketoacidosis induced by sodium-glucose cotransporter 2 inhibitor in the setting of prolonged fasting: a case report. *J Med Case Rep* 2022; **16**: 138 [PMID: 35346357 DOI: 10.1186/s13256-022-03347-1]
- 8 **Allison R**, Goldstein D, Musso MW. Challenges in the Diagnosis of Euglycemic Diabetic Ketoacidosis in a Patient With Multiple Sclerosis Taking a Sodium-Glucose Cotransporter 2 Inhibitor. *J Emerg Med* 2019; **57**: e1-e3 [PMID: 31027990 DOI: 10.1016/j.jemermed.2019.03.011]
- 9 **Almazrouei R**, Alkindi F, Alshamsi A, Dawoud T, Chaaban A, Rahman MU. Severe Prolonged SGLT2i-induced Euglycemic Diabetic Ketoacidosis Refractory to Standard Therapy and Dialysis: Case Report and Literature Review. *Oman Med J* 2022; **37**: e373 [PMID: 35712376 DOI: 10.5001/omj.2022.17]
- 10 **Altowayan WM**. Empagliflozin induced euglycemic diabetic ketoacidosis. A case reports. *Ann Med Surg (Lond)* 2022; **84**: 104879 [PMID: 36582864 DOI: 10.1016/j.amsu.2022.104879]

- 11 **Andrews TJ**, Cox RD, Parker C, Kolb J. Euglycemic Diabetic Ketoacidosis with Elevated Acetone in a Patient Taking a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor. *J Emerg Med* 2017; **52**: 223-226 [PMID: 27717592 DOI: 10.1016/j.jemermed.2016.07.082]
- 12 **Bader N**, Mirza L. Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin. *Pak J Med Sci* 2016; **32**: 786-788 [PMID: 27375734 DOI: 10.12669/pjms.323.9201]
- 13 **Badwal K**, Tariq T, Peirce D. Dapagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient Presenting with Acute Pancreatitis. *Case Rep Endocrinol* 2018; **2018**: 6450563 [PMID: 30159178 DOI: 10.1155/2018/6450563]
- 14 **Banakh I**, Kung R, Gupta S, Matthiesson K, Tiruvoipati R. Euglycemic diabetic ketoacidosis in association with dapagliflozin use after gastric sleeve surgery in a patient with type II diabetes mellitus. *Clin Case Rep* 2019; **7**: 1087-1090 [PMID: 31110751 DOI: 10.1002/ccr3.2147]
- 15 **Batista DV**, Vieira CAFA, Costa TA, Lima EG. COVID-19-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes on SGLT2 inhibitor: a case report. *Diabetol Int* 2021; **12**: 313-316 [PMID: 33133998 DOI: 10.1007/s13340-020-00473-3]
- 16 **Benmoussa JA**, Clarke M, Penmetsa A, Leykina L, Diaz K, Otterbeck P. Euglycemic diabetic ketoacidosis: The clinical concern of SGLT2 inhibitors. *J Clin Transl Endocrinol Case Rep* 2016;**2**:17 9. [DOI:10.1016/j.jecr.2016.05.002]
- 17 **Bilgin S**, Duman TT, Kurtkulagi O, Yilmaz F, Aktas G. A Case of Euglycemic Diabetic Ketoacidosis due to Empagliflozin Use in a Patient with Type 1 Diabetes Mellitus. *J Coll Physicians Surg Pak* 2022; **32**: 928-930 [PMID: 35795946 DOI: 10.29271/jcpsp.2022.07.928]
- 18 **Bitar ZI**, Maadarani OS, Alabdali F, Team A, Elsayah W, Mohsen MJ, Elzouairy MM. Sodium-glucose cotransporter-2 inhibitors induced euglycemic diabetic ketoacidosis: Two case reports and a review of the literature. *Clin Case Rep* 2022; **10**: e05440 [PMID: 35169474 DOI: 10.1002/ccr3.5440]
- 19 **Brown F**, McColl T. Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin Use: A Case Report. *J Emerg Med* 2018; **54**: 109-111 [PMID: 29157798 DOI: 10.1016/j.jemermed.2017.10.001]
- 20 **Bteich F**, Daher G, Kapoor A, Charbek E, Kamel G. Post-surgical Euglycemic Diabetic Ketoacidosis in a Patient on Empagliflozin in the Intensive Care Unit. *Cureus* 2019; **11**: e4496 [PMID: 31259114 DOI: 10.7759/cureus.4496]
- 21 **Calçada MB**, Fernandes L, Soares Costa R, Montezinho S, Martins Duarte F, Frutuoso L, Freitas AR. Euglycemic Diabetic Ketoacidosis after a Single Dose of Empagliflozin in a Patient

with Pancreatitis. *Clin Pract* 2021; **11**: 216-218 [PMID: 33917274 DOI: 10.3390/clinpract11020031]

22 **Candelario N**, Wykretowicz J. The DKA that wasn't: a case of euglycemic diabetic ketoacidosis due to empagliflozin. *Oxf Med Case Reports* 2016; **2016**: 144-146 [PMID: 27471597 DOI: 10.1093/omcr/omw061]

23 **Chacko B**, Whitley M, Beckmann U, Murray K, Rowley M. Postoperative euglycaemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitors (gliflozins): a report of two cases and review of the literature. *Anaesth Intensive Care* 2018; **46**: 215-219 [PMID: 29519226 DOI: 10.1177/0310057X1804600212]

24 **Chao HY**, Kornelius E. Two alcoholic liver cirrhosis patients developed diabetic ketoacidosis after SGLT2 inhibitors-prescription. *J Formos Med Assoc* 2020; **119**: 1886-1887 [PMID: 32690358 DOI: 10.1016/j.jfma.2020.07.013]

25 **Chaudhry A**, Roels C, Lee J. Sodium-Glucose Cotransporter-2 Inhibitor-associated Euglycemic Diabetic Ketoacidosis: Lessons From a Case Series of 4 Patients Undergoing Coronary Artery Bypass Grafting Surgery. *Can J Diabetes* 2022; **46**: 843-850 [PMID: 36068154 DOI: 10.1016/j.jcjd.2022.06.007]

26 **Chou YM**, Seak CJ, Goh ZNL, Seak JC, Seak CK, Lin CC. Euglycemic diabetic ketoacidosis caused by dapagliflozin: A case report. *Medicine (Baltimore)* 2018; **97**: e11056 [PMID: 29923997 DOI: 10.1097/MD.00000000000011056]

27 **Chow YY**, Worsley R, Topliss DJ. Lessons from the bedside: ketoacidosis and SGLT2 inhibitors. *Med J Aust* 2016; **205**: 191-192 [PMID: 27510353 DOI: 10.5694/mja16.00435]

28 **Clement M**, Senior P. Euglycemic diabetic ketoacidosis with canagliflozin: Not-so-sweet but avoidable complication of sodium-glucose cotransporter-2 inhibitor use. *Can Fam Physician* 2016; **62**: 725-728 [PMID: 27629668]

29 **Dai Z**, Nishihata Y, Kawamatsu N, Komatsu I, Mizuno A, Shimizu M, Toya N, Ishimatsu S, Komiyama N. Cardiac arrest from acute myocardial infarction complicated with sodium-glucose cotransporter 2 inhibitor-associated ketoacidosis. *J Cardiol Cases* 2017; **15**: 56-60 [PMID: 30546697 DOI: 10.1016/j.jccase.2016.10.006]

30 **Diaz-Ramos A**, Eilbert W, Marquez D. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature. *Int J Emerg Med* 2019; **12**: 27 [PMID: 31488052 DOI: 10.1186/s12245-019-0240-0]

31 **Dizon S**, Keely EJ, Malcolm J, Arnaout A. Insights Into the Recognition and Management of SGLT2-Inhibitor-Associated Ketoacidosis: It's Not Just Euglycemic Diabetic Ketoacidosis. *Can J Diabetes* 2017; **41**: 499-503 [PMID: 28797889 DOI: 10.1016/j.jcjd.2017.05.004]

- 32 **Dorcely B**, Nitis J, Schwartzbard A, Newman JD, Goldberg IJ, Sum M. A Case Report: Euglycemic Diabetic Ketoacidosis Presenting as Chest Pain in a Patient on a Low Carbohydrate Diet. *Curr Diabetes Rev* 2021; **17**: 243-246 [PMID: 32178617 DOI: 10.2174/1573399816666200316112709]
- 33 **Dull RB**, Spangler ML, Knezevich EL, Lau BM. Euglycemic Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes Mellitus Receiving Oral Therapy. *J Pharm Pract* 2019; **32**: 240-243 [PMID: 29241389 DOI: 10.1177/0897190017748049]
- 34 **Dyatlova N**, Omotosho YB, Sherchan R, Shrestha J, Buddharaju V. A Case of Severe Metabolic Acidosis due to Jardiance-Induced Euglycemic Diabetic Ketoacidosis. *Cureus* 2021; **13**: e14580 [PMID: 33889468 DOI: 10.7759/cureus.14580]
- 35 **Earle M**, Ault B, Bonney C. Euglycemic Diabetic Ketoacidosis in Concurrent Very Low-carbohydrate Diet and Sodium-glucose Transporter-2 Inhibitor Use: A Case Report. *Clin Pract Cases Emerg Med* 2020; **4**: 185-188 [PMID: 32426668 DOI: 10.5811/cpcem.2020.2.45904]
- 36 **Elshimy G**, Correa R. Sudden-onset Hypoglycemia Following Fluid Replacement in a Patient with Dapagliflozin-induced Diabetic Ketoacidosis Without Prior Insulin Use: Case Report. *Cureus* 2019; **11**: e5448 [PMID: 31489272 DOI: 10.7759/cureus.5448]
- 37 **Fang J**, Genco M, Caskey RN. COVID-19 Precipitating Euglycaemic Diabetic Ketoacidosis with SGLT2 Inhibitor Use. *Eur J Case Rep Intern Med* 2020; **7**: 001943 [PMID: 33194873 DOI: 10.12890/2020_001943]
- 38 **Fernandez Felix DA**, Madrigal Loria G, Sharma S, Sharma S, Arias Morales CE. A Rare Case of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis Obscured by Alkalosis. *Cureus* 2022; **14**: e25818 [PMID: 35698468 DOI: 10.7759/cureus.25818]
- 39 **Fukuda M**, Nabeta M, Muta T, Fukami K, Takasu O. Euglycemic diabetic ketoacidosis caused by canagliflozin: a case report. *Int J Emerg Med* 2020; **13**: 2 [PMID: 31969112 DOI: 10.1186/s12245-020-0261-8]
- 40 **Fukuyama Y**, Numata K, Yoshino K, Santanda T, Funakoshi H. Euglycemic diabetic ketoacidosis due to a strict low-carbohydrate diet during treatment with sodium-glucose cotransporter 2 inhibitors. *Acute Med Surg* 2020; **7**: e480 [PMID: 31988792 DOI: 10.1002/ams2.480]
- 41 **Gajjar K**, Luthra P. Euglycemic Diabetic Ketoacidosis in the Setting of SGLT2 Inhibitor Use and Hypertriglyceridemia: A Case Report and Review of Literature. *Cureus* 2019; **11**: e4384 [PMID: 31218148 DOI: 10.7759/cureus.4384]

- 42 **Gammons DT**, Counselman FL. Sodium-glucose Cotransporter-2 Induced Diabetic Ketoacidosis with Minimal Hyperglycemia. *Clin Pract Cases Emerg Med* 2018; **2**: 47-50 [PMID: 29849291 DOI: 10.5811/cpcem.2017.12.36213]
- 43 **Ghosh MSA**. A Case of Euglycemic Diabetic Keto Acidosis. *Indian J Endocrinol Metab* 2019; **23**: 500-501 [PMID: 31741915 DOI: 10.4103/ijem.IJEM_302_19]
- 44 **Goto S**, Ishikawa JY, Idei M, Iwabuchi M, Namekawa M, Nomura T. Life-Threatening Complications Related to Delayed Diagnosis of Euglycemic Diabetic Ketoacidosis Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Report of 2 Cases. *Am J Case Rep* 2021; **22**: e929773 [PMID: 33723205 DOI: 10.12659/AJCR.929773]
- 45 **Harati H**, Sharma V, Motazed A. Sodium-glucose cotransporter 2 inhibitor-associated diabetic ketoacidosis: Report of two cases with hyperglycemic ketoacidosis in type 1 diabetes. *J Diabetes* 2016; **8**: 165 [PMID: 26211700 DOI: 10.1111/1753-0407.12330]
- 46 **Hoffman C**, Green M, Megafu O. Sodium-glucose linked transporter 2 inhibitor-associated perioperative euglycaemic diabetic ketoacidosis: a case for a perioperative guideline. *Anaesth Intensive Care* 2017; **45**: 758 [PMID: 29137588]
- 47 **Hussaini SA**, Aziz A, Musa M, Alamin M, Danjuma M. Late-Onset Euglycemic Diabetic Ketoacidosis in a Patient With Massive Stroke Requiring Decompressive Craniectomy: A Case Report. *Cureus* 2021; **13**: e18629 [PMID: 34765377 DOI: 10.7759/cureus.18629]
- 48 **Iqbal I**, Hamid M, Khan MAA, Kainat A, Tariq S. Dapagliflozin-induced Late-onset Euglycemic Diabetic Ketoacidosis. *Cureus* 2019; **11**: e6089 [PMID: 31857921 DOI: 10.7759/cureus.6089]
- 49 **Isaacs M**, Tonks KT, Greenfield JR. Euglycaemic diabetic ketoacidosis in patients using sodium-glucose co-transporter 2 inhibitors. *Intern Med J* 2017; **47**: 701-704 [PMID: 28580740 DOI: 10.1111/imj.13442]
- 50 **Jazi M**, Porfiris G. Euglycemic diabetic ketoacidosis in type 2 diabetes treated with a sodium-glucose cotransporter-2 inhibitor. *Can Fam Physician* 2016; **62**: 722-724 [PMID: 27629667]
- 51 **Kang CY**, Khamooshi P, Reyes Pinzon V. An Unsuspected Case of Euglycemic Diabetic Ketoacidosis With Twists. *Cureus* 2022; **14**: e24016 [PMID: 35573514 DOI: 10.7759/cureus.24016]
- 52 **Kapila V**, Topf J. Sodium-Glucose Co-transporter 2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis After Bariatric Surgery: A Case and Literature Review. *Cureus* 2021; **13**: e17093 [PMID: 34527480 DOI: 10.7759/cureus.17093]

- 53 **Karakaya Z**, Topal FE, Topal F, Payza U, Akyol PY. Euglycemic diabetic ketoacidotic coma caused by dapagliflozin. *Am J Emerg Med* 2018; **36**: 2136.e1-2136.e2 [PMID: 30150107 DOI: 10.1016/j.ajem.2018.08.054]
- 54 **Kasbawala K**, Stamatiades GA, Majumdar SK. Fournier's Gangrene and Diabetic Ketoacidosis Associated with Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Life-Threatening Complications. *Am J Case Rep* 2020; **21**: e921536 [PMID: 32483108 DOI: 10.12659/AJCR.921536]
- 55 **Kelmenson DA**, Burr K, Azhar Y, Reynolds P, Baker CA, Rasouli N. Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin. *J Investig Med High Impact Case Rep* 2017; **5**: 2324709617712736 [PMID: 28634592 DOI: 10.1177/2324709617712736]
- 56 **Kietaibl AT**, Fasching P, Glaser K, Petter-Puchner AH. New Diabetic Medication Sodium-Glucose Cotransporter-2 Inhibitors Can Induce Euglycemic Ketoacidosis and Mimic Surgical Diseases: A Case Report and Review of Literature. *Front Surg* 2022; **9**: 828649 [PMID: 35402477 DOI: 10.3389/fsurg.2022.828649]
- 57 **Kitahara C**, Morita S, Kishimoto S, Matsuno S, Uraki S, Takeshima K, Furukawa Y, Inaba H, Iwakura H, Ariyasu H, Furuta H, Nishi M, Akamizu T. Early detection of euglycemic ketoacidosis during thoracic surgery associated with empagliflozin in a patient with type 2 diabetes: A case report. *J Diabetes Investig* 2021; **12**: 664-667 [PMID: 32686282 DOI: 10.1111/jdi.13365]
- 58 **Koch RA**, Clark RF. Euglycemic Ketoacidosis With Sodium-Glucose Cotransporter-2 Inhibitor. *Am J Ther* 2018; **25**: e590-e591 [PMID: 28452848 DOI: 10.1097/MJT.0000000000000602]
- 59 **Kuchay MS**, Mishra SK, Mehta Y. Empagliflozin induced euglycemic diabetic ketoacidosis in a patient undergoing coronary artery bypass graft despite discontinuation of the drug 48 hours prior to the surgery. *Diabetes Metab Syndr* 2021; **15**: 909-911 [PMID: 33915345 DOI: 10.1016/j.dsx.2021.04.016]
- 60 **Kum-Nji JS**, Gosmanov AR, Steinberg H, Dagogo-Jack S. Hyperglycemic, high anion-gap metabolic acidosis in patients receiving SGLT-2 inhibitors for diabetes management. *J Diabetes Complications* 2017; **31**: 611-614 [PMID: 27913012 DOI: 10.1016/j.jdiacomp.2016.11.004]
- 61 **Lakušić N**, Sopek Merkaš I, Slišković AM, Cerovec D. Euglycemic diabetic ketoacidosis: A rare but serious side effect of sodium-glucose co-transporter 2 inhibitors. *World J Cardiol* 2022; **14**: 561-564 [PMID: 36339887 DOI: 10.4330/wjc.v14.i10.561]
- 62 **Lane S**, Paskar D, Hamed S, Goffi A. When Guidelines Fail: Euglycemic Diabetic Ketoacidosis After Bariatric Surgery in a Patient Taking a Sodium-Glucose Cotransporter-2

Inhibitor: A Case Report. *A A Pract* 2018; **11**: 46-48 [PMID: 29634546 DOI: 10.1213/XAA.0000000000000734]

63 **Latif A**, Gastelum AA, Sood A, Reddy JT. Euglycaemic diabetic ketoacidosis in a 43-year-old woman with type 2 diabetes mellitus on SGLT-2 inhibitor (empagliflozin). *Drug Ther Bull* 2021; **59**: 93-95 [PMID: 33509834 DOI: 10.1136/dtb.2021.235117rep]

64 **Lau A**, Bruce S, Wang E, Ree R, Rondi K, Chau A. Perioperative implications of sodium-glucose cotransporter-2 inhibitors: a case series of euglycemic diabetic ketoacidosis in three patients after cardiac surgery. *Can J Anaesth* 2018; **65**: 188-193 [PMID: 29168157 DOI: 10.1007/s12630-017-1018-6]

65 **Leader R**, Cowen J, Rajeev SP. Dapagliflozin (SGLT2-i) induced euglycaemic diabetic ketoacidosis. *BMJ Case Rep* 2019; **12** [PMID: 31537607 DOI: 10.1136/bcr-2019-231104]

66 **Lee IH**, Ahn DJ. Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus: A case report. *Medicine (Baltimore)* 2020; **99**: e20228 [PMID: 32481295 DOI: 10.1097/MD.00000000000020228]

67 **Levine JA**, Karam SL, Aleppo G. SGLT2-I in the Hospital Setting: Diabetic Ketoacidosis and Other Benefits and Concerns. *Curr Diab Rep* 2017; **17**: 54 [PMID: 28597228 DOI: 10.1007/s11892-017-0874-3]

68 **Lin YH**. Sodium-glucose cotransporter-2 inhibitors induced eu-glycemic diabetic ketoacidosis: The first report in a type 2 diabetic (T2D) Taiwanese and literature review of possible pathophysiology and contributing factors. *J Formos Med Assoc* 2018; **117**: 849-854 [PMID: 29477576 DOI: 10.1016/j.jfma.2018.02.004]

69 **Lindsay PJ**, Gibson LE, Bittner EA, Berg S, Chang MG. Sodium-glucose cotransporter-2 (SGLT2) inhibitor-induced euglycemic diabetic ketoacidosis complicating the perioperative management of a patient with type 2 diabetes mellitus (T2DM) and Fournier's gangrene: A case report. *Int J Surg Case Rep* 2020; **77**: 463-466 [PMID: 33395826 DOI: 10.1016/j.ijscr.2020.11.037]

70 **Lucero P**, Chapela S. Euglycemic Diabetic Ketoacidosis in the ICU: 3 Case Reports and Review of Literature. *Case Rep Crit Care* 2018; **2018**: 1747850 [PMID: 30364093 DOI: 10.1155/2018/1747850]

71 **Mackintosh C**, Tewari A, Siegel J, Wang RD, Freeman W. Postoperative Euglycemic Diabetic Ketoacidosis and Encephalopathy Related to SGLT-2 Inhibitors: A Case Report and Discussion of Diabetes Treatment and "Sweet Pee Encephalopathy" in Perioperative Hospital Management. *Neurohospitalist* 2020; **10**: 51-54 [PMID: 31839866 DOI: 10.1177/1941874419835035]

- 72 **Mahfooz RS**, Khan MK, Al Hennawi H, Khedr A. SGLT-2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A Case Report and a Literature Review. *Cureus* 2022; **14**: e26267 [PMID: 35911365 DOI: 10.7759/cureus.26267]
- 73 **Masuta P**, Johri G, Paul M. SGLT2 Inhibitors and Euglycemic Ketoacidosis. *Am J Ther* 2018; **25**: e498-e500 [PMID: 28537992 DOI: 10.1097/MJT.0000000000000587]
- 74 **Matli VVK**, Fariduddin MM, Asafo-Agyei KO, Bansal N. Normoglycemic diabetic ketoacidosis in a type 2 diabetes patient on dapagliflozin: A case report. *Clin Case Rep* 2021; **9**: e05144 [PMID: 34917366 DOI: 10.1002/ccr3.5144]
- 75 **Mendelsohn RA**, Taveras AN, Mazer BA, Clayton LM. Euglycemic Diabetic Ketoacidosis Precipitated by SGLT-2 Inhibitor Use, Pericarditis, and Fasting: A Case Report. *Clin Pract Cases Emerg Med* 2020; **4**: 389-392 [PMID: 32926693 DOI: 10.5811/cpcem.2020.4.46056]
- 76 **Menghoum N**, Oriot P, Hermans MP. Clinical and biochemical characteristics and analysis of risk factors for euglycaemic diabetic ketoacidosis in type 2 diabetic individuals treated with SGLT2 inhibitors: A review of 72 cases over a 4.5-year period. *Diabetes Metab Syndr* 2021; **15**: 102275 [PMID: 34562870 DOI: 10.1016/j.dsx.2021.102275]
- 77 **Mistry S**, Eschler DC. Euglycemic Diabetic Ketoacidosis Caused by SGLT2 Inhibitors and a Ketogenic Diet: A Case Series and Review of Literature. *AACE Clin Case Rep* 2021; **7**: 17-19 [PMID: 33851013 DOI: 10.1016/j.aace.2020.11.009]
- 78 **Miwa M**, Nakajima M, Kaszynski RH, Goto H. Prolonged euglycemic diabetic ketoacidosis triggered by a single dose of sodium-glucose cotransporter 2 inhibitor. *BMJ Case Rep* 2020; **13** [PMID: 33028568 DOI: 10.1136/bcr-2020-235969]
- 79 **Nappi F**, La Verde A, Carfora G, Garofalo C, Provenzano M, Sasso FC, De Nicola L. Nephrology Consultation for Severe SGLT2 Inhibitor-Induced Ketoacidosis in Type 2 Diabetes: Case Report. *Medicina (Kaunas)* 2019; **55** [PMID: 31405158 DOI: 10.3390/medicina55080462]
- 80 **Nishida A**, Ogawa O, Takizawa H. Detection of Euglycemic Diabetic Ketoacidosis During Thoracic Surgery 75 Hours After Empagliflozin Discontinuation. *Cureus* 2022; **14**: e29974 [PMID: 36381945 DOI: 10.7759/cureus.29974]
- 81 **Nolan BJ**, Varadarajan S, Furlanos S, Neoh SL. Beware Ketoacidosis with SGLT2 Inhibitors in Latent Autoimmune Diabetes of the Adult. *Am J Med* 2020; **133**: e422-e424 [PMID: 31923401 DOI: 10.1016/j.amjmed.2019.12.006]
- 82 **Oriot P**, Hermans MP. Euglycemic diabetic ketoacidosis in a patient with type 1 diabetes and SARS-CoV-2 pneumonia: case-report and review of the literature. *Acta Clin Belg* 2022; **77**: 113-117 [PMID: 32544373 DOI: 10.1080/17843286.2020.1780390]

- 83 **Osafehinti DA**, Okoli OJ, Karam JG. A Case of SGLT2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis Following Coronary Artery Bypass Surgery. *AACE Clin Case Rep* 2021; **7**: 20-22 [PMID: 33851014 DOI: 10.1016/j.aace.2020.11.014]
- 84 **Ozer O**, Yorulmaz G. Euglycemic Diabetic Ketoacidosis Associated with Empagliflozin Use in the Course of the SARS-Cov-2 Pandemic. *J Coll Physicians Surg Pak* 2020; **30**: 110-111 [PMID: 33115581 DOI: 10.29271/jcpsp.2020.suppl2.110]
- 85 **Pace DJ**, Dukleska K, Phillips S, Gleason V, Yeo CJ. Euglycemic Diabetic Ketoacidosis Due to Sodium-Glucose Cotransporter 2 Inhibitor Use in Two Patients Undergoing Pancreatectomy. *J Pancreat Cancer* 2018; **4**: 95-99 [PMID: 30631862 DOI: 10.1089/pancan.2018.0016]
- 86 **Papadokostaki E**, Liberopoulos E. Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy. *Case Rep Endocrinol* 2019; **2019**: 3901741 [PMID: 31198610 DOI: 10.1155/2019/3901741]
- 87 **Pathak BD**, Dhakal B, Bhattarai AM, Regmi BU, Mandal SK, Panta PR, Khadka S, Simkhada N. Euglycemic diabetic ketoacidosis in a patient with acute stroke taking sodium glucose co-transporter 2 inhibitor. *Ann Med Surg (Lond)* 2022; **79**: 104118 [PMID: 35860094 DOI: 10.1016/j.amsu.2022.104118]
- 88 **Paul N**, Jonklaas J. Low carbohydrate diet while taking dapagliflozin: A case report and review of literature. *Diabetes Metab Syndr* 2021; **15**: 361-363 [PMID: 33517150 DOI: 10.1016/j.dsx.2021.01.016]
- 89 **Pereyra A M**, Ramírez C, Román R. [Euglycemic ketosis in an adolescent with type 1 diabetes on insulin and dapagliflozin: Case report]. *Rev Chil Pediatr* 2017; **88**: 404-410 [PMID: 28737202 DOI: 10.4067/S0370-41062017000300015]
- 90 **Peters AL**, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. *Diabetes Care* 2015; **38**: 1687-1693 [PMID: 26078479 DOI: 10.2337/dc15-0843]
- 91 **Pujara S**, Ioachimescu A. Prolonged Ketosis in a Patient With Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin. *J Investig Med High Impact Case Rep* 2017; **5**: 2324709617710040 [PMID: 28589154 DOI: 10.1177/2324709617710040]
- 92 **Quarella M**, Walser D, Brändle M, Fournier JY, Bilz S. Rapid Onset of Diabetic Ketoacidosis After SGLT2 Inhibition in a Patient With Unrecognized Acromegaly. *J Clin Endocrinol Metab* 2017; **102**: 1451-1453 [PMID: 28323955 DOI: 10.1210/jc.2017-00082]

- 93 **Rafey MF**, Butt A, Coffey B, Reddington L, Devitt A, Lappin D, Finucane FM. Prolonged acidosis is a feature of SGLT2i-induced euglycaemic diabetic ketoacidosis. *Endocrinol Diabetes Metab Case Rep* 2019; **2019** [PMID: 31600728 DOI: 10.1530/EDM-19-0087]
- 94 **Ramirez Tello EM**, Orellana-Barrios MA, Nugent K. Sodium-glucose Cotransporter 2 Inhibitor-induced Diabetic Ketoacidosis in a Type 2 Diabetic Patient. *Am J Med Sci* 2016; **351**: 634-635 [PMID: 27238930 DOI: 10.1016/j.amjms.2016.03.014]
- 95 **Rao SJ**, Kumar K, Saleh N. A Case of SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis. *Cureus* 2022; **14**: e30106 [PMID: 36381906 DOI: 10.7759/cureus.30106]
- 96 **Rashid O**, Farooq S, Kiran Z, Islam N. Euglycaemic diabetic ketoacidosis in a patient with type 2 diabetes started on empagliflozin. *BMJ Case Rep* 2016; **2016** [PMID: 27177938 DOI: 10.1136/bcr-2016-215340]
- 97 **Sampani E**, Sarafidis P, Dimitriadis C, Kasimatis E, Daikidou D, Bantis K, Papanikolaou A, Papagianni A. Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin: case report and literature review. *BMC Nephrol* 2020; **21**: 276 [PMID: 32669085 DOI: 10.1186/s12882-020-01930-6]
- 98 **Sanusi I**, Sarnowski A, Russell-Jones D, Forni LG. A potential diagnostic problem on the ICU: Euglycaemic diabetic Ketoacidosis associated with SGLT2 inhibition. *J Crit Care* 2020; **57**: 19-22 [PMID: 32007835 DOI: 10.1016/j.jcrc.2019.12.007]
- 99 **Seger CD**, Xing H, Wang L, Shin JS. Intraoperative Diagnosis of Sodium-Glucose Cotransporter 2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A Case Report. *A A Pract* 2021; **15**: e01380 [PMID: 33512907 DOI: 10.1213/XAA.0000000000001380]
- 100 **Sethi SM**, Vohra M, Ali SA. Euglycemic diabetic ketoacidosis (EDKA) in a patient receiving dapagliflozin. *Acta Endocrinol (Buchar)* 2021; **17**: 266-269 [PMID: 34925578 DOI: 10.4183/aeb.2021.266]
- 101 **Sexe J**, Mayes C, Tofts P. Euglycemic Diabetic Ketoacidosis in a Lung Cancer Patient Using Empagliflozin. *Case Rep Crit Care* 2020; **2020**: 7437892 [PMID: 32695525 DOI: 10.1155/2020/7437892]
- 102 **Shah M**, Pathrose E, Bhagwat NM, Chandy D. "The Bitter Truth of Sugar"-Euglycemic Diabetic Ketoacidosis due to Sodium-glucose Cotransporter-2 Inhibitors: A Case Series. *Indian J Crit Care Med* 2022; **26**: 123-126 [PMID: 35110855 DOI: 10.5005/jp-journals-10071-24076]
- 103 **Sharma PV**, Jobanputra YB, Lewin K, Bagatell S, Lichtstein DM. Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series. *Rev Recent Clin Trials* 2018; **13**: 156-160 [PMID: 29542418 DOI: 10.2174/1574887113666180314101436]

- 104 **Singh S**, Rushakoff RJ, Neinstein AB. A Case Report of Diabetic Ketoacidosis With Combined Use of a Sodium Glucose Transporter 2 Inhibitor and Hybrid Closed-Loop Insulin Delivery. *J Diabetes Sci Technol* 2019; **13**: 605-606 [PMID: 30931610 DOI: 10.1177/1932296819838875]
- 105 **Sinha S**, Gavaghan D, Yew S. Euglycaemic ketoacidosis from an SGLT2 inhibitor exacerbated by a ketogenic diet. *Med J Aust* 2020; **212**: 46-46.e1 [PMID: 31789435 DOI: 10.5694/mja2.50434]
- 106 **Soni P**, Kumar V, Saradna A, Kupfer Y. Empagliflozin-Associated Euglycemic Diabetic Ketoacidosis. *Am J Ther* 2018; **25**: e740-e741 [PMID: 29746292 DOI: 10.1097/MJT.0000000000000752]
- 107 **Steinmetz-Wood S**, Gilbert M, Menson K. A Case of Diabetic Ketoacidosis in a Patient on an SGLT2 Inhibitor and a Ketogenic Diet: A Critical Trio Not to Be Missed. *Case Rep Endocrinol* 2020; **2020**: 8832833 [PMID: 32855828 DOI: 10.1155/2020/8832833]
- 108 **Storgaard H**, Bagger JI, Knop FK, Vilsbøll T, Rungby J. Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Treatment. *Basic Clin Pharmacol Toxicol* 2016; **118**: 168-170 [PMID: 26291182 DOI: 10.1111/bcpt.12457]
- 109 **Tahir H**, Wani A, Daruwalla V, Daboul N, Sagi J. Euglycemic diabetic ketoacidosis and severe acute kidney injury secondary to off label use of sodium glucose cotransporter-2 inhibitor in a type-1 diabetic patient. *J Ayub Med Coll Abbottabad* 2015; **27**: 923-924 [PMID: 27004352]
- 110 **Tougaard NH**, Faber J, Eldrup E. Very low carbohydrate diet and SGLT-2-inhibitor: double jeopardy in relation to ketoacidosis. *BMJ Case Rep* 2019; **12** [PMID: 30954957 DOI: 10.1136/bcr-2018-227516]
- 111 **van Niekerk C**, Wallace J, Takata M, Yu R. Euglycaemic diabetic ketoacidosis in bariatric surgery patients with type 2 diabetes taking canagliflozin. *BMJ Case Rep* 2018; **2018** [PMID: 30131409 DOI: 10.1136/bcr-2017-221527]
- 112 **Velasco de Cos G**, Sánchez-Molina Acosta MI, Fernández MMT. Diabetic Euglycemic Ketoacidosis Induced by Oral Antidiabetics Type SGLT2i. *EJIFCC* 2021; **32**: 105-110 [PMID: 33753980]
- 113 **Vitale RJ**, Valtis YK, McDonnell ME, Palermo NE, Fisher NDL. Euglycemic Diabetic Ketoacidosis With COVID-19 Infection in Patients With Type 2 Diabetes Taking SGLT2 Inhibitors. *AACE Clin Case Rep* 2021; **7**: 10-13 [PMID: 33521255 DOI: 10.1016/j.aace.2020.11.019]
- 114 **Voskertchian A**, Milanes L. Case Report: DKA with Lower-than-Expected Blood Glucose in the Setting of SGLT2 Inhibitor Use. *Am Fam Physician* 2021; **103**: 200 [PMID: 33587584]

- 115 **Wan Azman SS**, Sukor N, Abu Shamsi MY, Ismail I, Kamaruddin NA. Case Report: High-Calorie Glucose Infusion and Tight Glycemic Control in Ameliorating Refractory Acidosis of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis. *Front Endocrinol (Lausanne)* 2022; **13**: 867647 [PMID: 35712244 DOI: 10.3389/fendo.2022.867647]
- 116 **Wang AY**, Hou SK, Li SJ, Kao WF. Euglycemic diabetic ketoacidosis in type 2 diabetes with sodium glucose cotransporter 2 inhibitors. *Am J Emerg Med* 2017; **35**: 379.e5-379.e6 [PMID: 27614369 DOI: 10.1016/j.ajem.2016.08.055]
- 117 **Wang KM**, Isom RT. SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis: A Case Report. *Kidney Med* 2020; **2**: 218-221 [PMID: 32734242 DOI: 10.1016/j.xkme.2019.12.006]
- 118 **Wasey W**, Hutchings S, Dufner A, Okon D, Saleh S. Fall, Fracture, and Two Episodes of Euglycemic Diabetic Ketoacidosis. *Cureus* 2022; **14**: e25788 [PMID: 35812537 DOI: 10.7759/cureus.25788]
- 119 **Wong YC**, Liu KL, Lee CL. Postoperative extremity gangrene in a patient with type 2 diabetes taking SGLT2 inhibitors: A case report. *Medicine (Baltimore)* 2021; **100**: e25590 [PMID: 33879720 DOI: 10.1097/MD.00000000000025590]
- 120 **Yamamoto M**, Ide N, Kitajima S, Obayashi M, Asada K, Matsushima S, Ito M. [Risk of Euglycemic Diabetic Ketoacidosis Due to Low-carbohydrate Diet While Taking Empagliflozin: a Case Report]. *Yakugaku Zasshi* 2019; **139**: 1479-1483 [PMID: 31685745 DOI: 10.1248/yakushi.19-00120]
- 121 **Yasuma T**, Okano Y, Tanaka S, Nishihama K, Eguchi K, Inoue C, Maki K, Uchida A, Uemura M, Suzuki T, D'Alessandro-Gabazza CN, Gabazza EC, Yano Y. Sodium-glucose co-transporter-2 inhibitor-associated euglycemic diabetic ketoacidosis that prompted the diagnosis of fulminant type-1 diabetes: A case report. *World J Clin Cases* 2021; **9**: 3163-3169 [PMID: 33969104 DOI: 10.12998/wjcc.v9.i13.3163]
- 122 **Yeo SM**, Park H, Paek JH, Park WY, Han S, Park SB, Jin K. Ketoacidosis with euglycemia in a patient with type 2 diabetes mellitus taking dapagliflozin: A case report. *Medicine (Baltimore)* 2019; **98**: e14150 [PMID: 30653152 DOI: 10.1097/MD.00000000000014150]
- 123 **Yii ESS**, Azli AW, Sitaram PN. Sodium-glucose cotransporter 2 inhibitor-induced euglycemic diabetic ketoacidosis in a patient with coronavirus disease 2019: a case report. *J Med Case Rep* 2022; **16**: 17 [PMID: 34983625 DOI: 10.1186/s13256-021-03232-3]
- 124 **Zhang L**, Tamilia M. Euglycemic diabetic ketoacidosis associated with the use of a sodium-glucose cotransporter-2 inhibitor. *CMAJ* 2018; **190**: E766-E768 [PMID: 29941433 DOI: 10.1503/cmaj.171319]

125 **Zughaib MT**, Patel K, Leka M, Affas S. Self-Induced Euglycemic Diabetic Ketoacidosis: When to Stop the Drip. *Cureus* 2022; **14**: e21768 [PMID: 35251838 DOI: 10.7759/cureus.21768]